摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲氧基-1,1-二甲基乙胺盐酸盐 | 251660-96-5

中文名称
2-甲氧基-1,1-二甲基乙胺盐酸盐
中文别名
——
英文名称
1-methoxy-2-methylpropan-2-amine hydrochloride
英文别名
(1-methoxymethyl-1-methyl)ethylamine hydrochloride;1-methoxy-2-methylprop-2-ylamine hydrochloride;2-amino-2-methyl-1-methoxypropane hydrochloride;2-methoxy-1,1-dimethylethylamine hydrochloride;1-methoxy-2-methyl-2-propanamine hydrochloride;(2-Methoxy-1,1-dimethylethyl)amine hydrochloride;1-methoxy-2-methylpropan-2-amine;hydrochloride
2-甲氧基-1,1-二甲基乙胺盐酸盐化学式
CAS
251660-96-5
化学式
C5H13NO*ClH
mdl
MFCD16036163
分子量
139.625
InChiKey
PNJWRLMQZGHSPA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.02
  • 重原子数:
    8
  • 可旋转键数:
    2
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    35.2
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
    申请人:GILEAD SCIENCES INC
    公开号:WO2017205115A1
    公开(公告)日:2017-11-30
    The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.
    本公开涉及一般与化合物和药物组合物有关,这些化合物和药物组合物可用于治疗乙型肝炎病毒感染的方法。
  • [EN] AMIDES AS PIM INHIBITORS<br/>[FR] AMIDES CONVENANT COMME INHIBITEURS DES PIM
    申请人:AMGEN INC
    公开号:WO2013130660A1
    公开(公告)日:2013-09-06
    The invention relates to amide-containing compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    本发明涉及式(1)的含酰胺化合物及其盐。在一些实施例中,本发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中,本发明涉及包含本文披露的化合物的药物组合物,及其用于预防治疗Pim激酶相关状况和疾病,尤其是癌症的应用。
  • 二氢嘧啶类化合物及其在药物中的应用
    申请人:广东东阳光药业有限公司
    公开号:CN109111451B
    公开(公告)日:2020-08-11
    本发明涉及一种二氢嘧啶类化合物及其作为药物的用途,尤其是作为治疗和预防乙型肝炎的药物的用途。具体地说,本发明涉及通式(I)或(Ia)所示的化合物或其对映异构体、非对映异构体、互变异构体、合物、溶剂化物或药学上可接受的盐,其中各变量如说明书所定义。本发明还涉及通式(I)或(Ia)所示的化合物或其对映异构体、非对映异构体、互变异构体、合物、溶剂化物或药学上可接受的盐作为药物的用途,尤其是作为治疗和预防乙型肝炎的药物的用途。
  • [EN] DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS DIHYDROPYRIMIDINE ET UTILISATIONS DE CEUX-CI EN MÉDECINE
    申请人:SUNSHINE LAKE PHARMA CO LTD
    公开号:WO2019001396A1
    公开(公告)日:2019-01-03
    Provided herein are a dihydropyrimidine compound and a pharmaceutical application thereof, especially the application used for treating and preventing HBV diseases. Specifically, provided herein is a compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicine, especially for treating and preventing HBV diseases.
    本文提供了一种二氢嘧啶化合物及其药物应用,特别是用于治疗和预防HBV疾病的应用。具体来说,本文提供了具有化学式(I)或(Ia)的化合物,或其对映体、异构体、互变异构体、合物、溶剂合物或其药用可接受的盐,其中化学式的变量如规范中定义。本文还提供了将具有化学式(I)或(Ia)的化合物,或其对映体、异构体、互变异构体、合物、溶剂合物或其药用可接受的盐用作药物的用途,特别是用于治疗和预防HBV疾病。
  • Cyanopyrrolidine derivatives
    申请人:——
    公开号:US20040072892A1
    公开(公告)日:2004-04-15
    A cyanopyrrolidine derivative represented by Formula (1): 1 [wherein R 1 is a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms, R 2 is a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms, or R 1 and R 2 together form an oxo, a hydroxyimino group, an alkoxyimino group having 1 to 5 carbon atoms or an alkylidene group having 1 to 5 carbon atoms, R 3 and R 4 are each a hydrogen atom, a halogen atom, a hydroxyl group, an alkoxy group having 1 to 5 carbon atoms or an alkyl group having 1 to 5 carbon atoms, or R 3 and R 4 together form an oxo, a hydroxyimino group, an alkoxyimino group having 1 to 5 carbon atoms or an alkylidene group having 1 to 5 carbon atoms, X is an oxygen atom or a sulfur atom, Y is —CR 5 R 6 — (wherein R 5 and R 6 are the same or different, and are each a hydrogen atom, a halogen atom, an optionally substituted alkyl group having 1 to 10 carbon atoms or an optionally substituted alkenyl group having 2 to 10 carbon atoms), or —CR 7 R 8 —CR 9 R 10 — (wherein R 7 , R 8 , R 9 and R 10 are the same or different, and each a hydrogen atom, a halogen atom or an optionally substituted alkyl group having 1 to 10 carbon atoms, or R 7 and R 9 together with the carbon atom to which they are attached form an optionally substituted cycloalkyl group having 3 to 8 carbon atoms, an optionally substituted cycloalkenyl group having 4 to 8 carbon atoms, an optionally substituted bicycloalkyl group having 5 to 10 carbon atoms, or an optionally substituted bicycloalkenyl group having 5 to 10 carbon atoms) and Z is a hydrogen atom or an optionally substituted alkyl group having 1 to 10 carbon atoms, or Y and Z together with the nitrogen atom to which they are attached form an optionally substituted cyclic amino group having 2 to 10 carbon atoms], or a pharmaceutically acceptable salt thereof.
    一种由式(1)表示的吡咯烷衍生物:1[其中R1是卤素原子,羟基,具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基,R2是氢原子,卤素原子,羟基,具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基,或R1和R2一起形成氧代,羟基,具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基亚甲基,R3和R4分别是氢原子,卤素原子,羟基,具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基,或R3和R4一起形成氧代,羟基,具有1至5个碳原子的烷氧基或具有1至5个碳原子的烷基亚甲基,X是氧原子或原子,Y是- CR5R6-(其中R5和R6相同或不同,且均为氢原子,卤素原子,具有1至10个碳原子的可选取代烷基或具有2至10个碳原子的可选取代烯基),或-CR7R8-CR9R10-(其中R7,R8,R9和R10相同或不同,且均为氢原子,卤素原子或具有1至10个碳原子的可选取代烷基,或R7和R9与它们附着的碳原子一起形成具有3至8个碳原子的可选取代环烷基,具有4至8个碳原子的可选取代环烯基,具有5至10个碳原子的可选取代双环烷基或具有5至10个碳原子的可选取代双环烯基),Z是氢原子或具有1至10个碳原子的可选取代烷基,或Y和Z与它们附着的氮原子一起形成具有2至10个碳原子的可选取代环基,或其药学上可接受的盐。
查看更多